Global Fabry Disease Drug Market - Industry Trends & Forecast to 2026

  • Pharmaceutical
  • Upcoming Report
  • Jul 2019
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Fabry Disease Drug Market By Type (Classic Fabry Disease and Atypical Late-Onset Fabry Disease), Treatment Type (Enzyme Replacement Therapy (ERT), Chaperone Treatment, Substrate Reduction Therapy (SRT) and Others), Mechanism of Action Type (Alpha-Galactosidase A (Alpha-Gal A) Agonist, Globotriaosylceramide (GL-3) Deposition Reducer, Pancreatic Replacement Enzymes, Pain Management and Others), Route of Administration Type (Oral and Injectable), End- users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends & Forecast to 2026

Market Analysis: Global Fabry Disease Drug Market

Global fabry disease drug market is increasing gradually substantial CAGR of 9.8% in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. Growing population of Fabry disease worldwide and extensive evaluation and adoption of advance technology in research and development for novel therapies are the factors which drive the market.

Market Definition: Global Fabry Disease Drug Market

Fabry disease is a rare genetic disorder caused by deficient activity of lysosomal enzyme called α-galactosidase A (α-Gal A) which results in dysfunction of glycosphingolipid (fat) metabolism. Lysosomal enzyme is responsible for break down complex sugar-lipid molecules called glycolipids or digests particular compounds. The deficient of this enzyme may results in cell abnormalities and organ system dysfunction which will affects particularly small blood vessels, the heart and kidneys.

According to the stats published in the U.S. National Library of Medicine, it is estimated 1 in every 40,000 to 60,000 males diagnosed with Fabry disease worldwide. This growing number of Fabry disease’s population worldwide and adoption of research and development for novel-disease-specific treatment are the key factors for market growth.

Market Drivers

  • Increases prevalence of Fabry disease worldwide
  • Vulnerable male population as it is more frequently occur in male
  • Emergence of drugs used in the treatment of risk associated with Fabry disease
  • Strategic collaboration and licensing deal between the companies

Market Restraints

  • Effective treatment is either unavailable or unaffordable
  • Patent expiry from many companies and introduction of generic drugs of branded version is expected to restrain the growth if the market

  • Inadequate knowledge about Fabry disease in some developing countries

Segmentation: Global Fabry Disease Drug Market

  • By Type

  • Classic Fabry Disease
  • Atypical Late-Onset Fabry Disease

  • By Treatment Type

  • Enzyme Replacement Therapy (ERT)
  • Chaperone Treatment
  • Substrate Reduction Therapy (SRT)
  • Others

By Mechanism of Action Type

  • Alpha-Galactosidase A (Alpha-Gal A) Agonist

    • Migalastat

  • Globotriaosylceramide (GL-3) Deposition Reducer

    • Agalsidase Beta

  • Pancreatic Replacement Enzymes

    • Pancrelipase

  • Pain Management

    • Opioids

  • Others

By Route of administration

  • Oral
  • Injectable

 By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Geography

  • North America

    • U.S.
    • Canada
    • Mexico

  • South America

    • Brazil
    • Rest of South America

  • Europe

    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe

  • Asia-Pacific

    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia Pacific

  • Middle East & Africa

    • South Africa
    • Rest of Middle East & Africa

Key Developments in the Market:

In November 2018, JCR Pharmaceuticals Co., Ltd in collaboration with Amicus Therapeutics, Inc, and GlaxoSmithKline plc launched Agalsidase Beta which is a biosimilar of Fabrazyme in the Japan for the treatment of the lysosomal storage disorder (LSD) Fabry disease (FD). The launch of biosimilar agalsidase beta product significantly improves the treatment option for patients suffering from Fabry disease in the Japan.

In May 2018, Amicus Therapeutics, Inc, launched Galafold (Migalastat), an oral enzyme replacement therapy for the treatment of Fabry disease in adult patients in the Japan. The launch of Galafold significantly change the treatment landscape for the patients throughout Japan as it is first and only oral precision medicine for Fabry disease in the Japan.

Competitive Analysis:

Global Fabry disease drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global fabry disease drug market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players:

Few of the major competitors currently working in the global fabry disease drug market are Sanofi, Takeda Pharmaceutical Company Limited, Amicus Therapeutics, Inc, Moderna, Inc, Greenovation Biotech GmbH, Plant-Based Proteins with Better Therapeutic Profiles, JCR Pharmaceuticals Co., Ltd, ISU ABXIS, Idorsia Pharmaceuticals Ltd, AVROBIO, Inc, Resverlogix Corp., Novartis AG, Pfizer Inc, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Enzyvant, CHIESI Farmaceutici SpA, and many others.

Research Methodology: Global Fabry Disease Drug Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

  • Current and future of global fabry disease drug market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players


Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

Please fill in the below form for detailed Inquire Before Buying

Choose License Type
  • $5400.00
  • $4200.00